Straits Times Index
3,308.67 +8.67 (+0.26%) Nikkei
38,643.91 +10.89 (+0.03%) Hang Seng
17,997.78 -337.54 (-1.84%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,542.68 -792.81 (-1.21%) CMC Crypto 200
1,351.67 -30.99 (-2.24%)
SNY Dec 2024 40.000 put
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 40.00 |
| Expiry date | 2024-12-20 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswirePress Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi’s commitment to bring potential first- and best-in-class treatments to the rare blood disorders communityInterim results from the long-term XTEND-ed phase 3 study demonstrate once-weekly ALTUVIIIO continues to provide highly effective bleed protectionNew ATLAS phase 3 study data reinforce the potential of fitusiran to provide prophylax
- GlobeNewswire
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. This agreement is designed to enable regional manufacturing of polio vaccines to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer of IPV
FortuneThe secrets of success with Paul Hudson, CEO of Sanofi, the leader who’s channeling AI to find the next pharma wonder drug
Today we meet with British CEO Paul Hudson to find out how he plans to build the Sanofi of tomorrow.
